Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

Després, Jean-Pierre, Golay, Alain, Sjöström, Lars·2005·New England Journal of Medicine

DOI 10.1056/nejmoa044537

Cited by (999)

Items 101–200 of 999

Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis
David R. Janero, Alexandros Makriyannis · 2009 · Expert Opinion on Emerging Drugs
Daily Cannabis Use: A Novel Risk Factor of Steatosis Severity in Patients With Chronic Hepatitis C
Christophe Hézode, Élie Serge Zafrani, Françoise Roudot‐Thoraval, Charlotte E. Costentin, A. Hessami, Magali Bouvier‐Alias, Fatiha Medkour, Jean–Michel Pawlotsky, Sophie Lotersztajn, Ariane Mallat · 2007 · Gastroenterology
Anti-obesity drugs: a review about their effects and their safety
Giuseppe Derosa, Pamela Maffioli · 2012 · Expert Opinion on Drug Safety
Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality
Naidu, Pattipati S., Varvel, Stephen A., Ahn, Kyunghye, Cravatt, Benjamin F., Martin, Billy R., Lichtman, Aron H. · 2007 · Psychopharmacology
Adipocytokines and Insulin Resistance
Eduardo Esteve, Wifredo Ricart, José Manuel Fernández‐Real · 2009 · Diabetes Care
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Maccarrone, Mauro, Di Marzo, Vincenzo, Gertsch, Jürg, Grether, Uwe, Howlett, Allyn C., Hua, Tian, Makriyannis, Alexandros, Piomelli, Daniele, Ueda, Natsuo, van der Stelt, Mario · 2023 · Pharmacological Reviews
Regression of Fibrosis after Chronic Stimulation of Cannabinoid CB2 Receptor in Cirrhotic Rats
Javier Muñoz, Josefa Ros, Guillermo Fernández‐Varo, Sònia Tugues, Manuel Morales‐Ruiz, Carlos E. Alvarez, Scott L. Friedman, Vicente Arroyo, Wladimiro Jiménez · 2007 · Journal of Pharmacology and Experimental Therapeutics
CNS regulation of appetite
Joanne Allison Harrold, Terence M. Dovey, John Edward Blundell, Jason C. G. Halford · 2012 · Neuropharmacology
The evolving definitions and increasing prevalence of the metabolic syndrome.
S. Desroches, B. Lamarche · 2007 · Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme
Hepatic Cannabinoid Receptor-1 Mediates Diet-Induced Insulin Resistance via Inhibition of Insulin Signaling and Clearance in Mice
Jie Liu, Liang Zhou, Keming Xiong, Grzegorz Godlewski, Bani Mukhopadhyay, Joseph Tam, Shi Yin, Peter Gao, Xin Shan, James M. Pickel et al. · 2012 · Gastroenterology
Visceral obesity and the heart
Patrick Mathieu, Philippe Pîbarot, Éric Larose, Paul Poirier, André Marette, Jean‐Pierre Després · 2008 · The International Journal of Biochemistry & Cell Biology
Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides
Reşat Çınar, Grzegorz Godlewski, Jie Liu, Joseph Tam, Tony Jourdan, Bani Mukhopadhyay, Judith Dale Harvey-White, George Kunos · 2013 · Hepatology
Metabolic Syndrome: From Global Epidemiology to Individualized Medicine
John A. Batsis, Ramfis E Nieto-Martínez, Francisco Alejandro López-Jiménez · 2007 · Clinical Pharmacology & Therapeutics
Adipose Tissue as an Endocrine Organ: An Update on Pro-inflammatory and Anti-inflammatory Microenvironment
Kvido Smitka, Dana Maresova · 2015 · Prague Medical Report
Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis
Meir S Steiner, Carsten Tobias Wotjak · 2008 · Progress in brain research
Metabolic Syndrome Negatively Influences Disease Progression and Prognosis in Aortic Stenosis
Martin Briand, Isabelle Lemieux, Jean Gaston Dumesnil, Patrick Mathieu, Amélie Cartier, Jean‐Pierre Després, Marie Arsenault, Jacques Couët, Philippe Pîbarot · 2006 · Journal of the American College of Cardiology
Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications
Andrew J. Krentz, Geraldine Frances Clough, Christopher D. Byrne · 2007 · Diabetes Obesity and Metabolism
Adiponectin and cardiovascular disease: state of the art?
Paul E. Szmitko, Hwee Teoh, Duncan J. Stewart, Subodh Verma · 2006 · American Journal of Physiology-Heart and Circulatory Physiology
Pharmacological Treatment of the Overweight Patient
George A. Bray, Frank L. Greenway · 2007 · Pharmacological Reviews
The future of endocannabinoid-oriented clinical research after CB1 antagonists
Bernard Le Foll, David A. Gorelick, Steven R. Goldberg · 2009 · Psychopharmacology
Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users
Marilyn Ann Huestis, Susan J. Boyd, Stephen J. Heishman, Kenzie L. Preston, DENIS BONNET, Gérard Le Fur, David A. Gorelick · 2007 · Psychopharmacology
Review article: current management of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis
Zobair M. Younossi · 2008 · Alimentary Pharmacology & Therapeutics
Controversies in hypertension
Norman M. Kaplan, Lionel Henry Opie · 2006 · The Lancet
Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re‐feeding
Angelo Antonio Izzo, Fabiana Piscitelli, Raffaele Capasso, Gabriella Aviello, Barbara Romano, Francesca Borrelli, Stefania Petrosino, Vincenzo Di Marzo · 2009 · British Journal of Pharmacology
CB1 Antagonism Exerts Specific Molecular Effects on Visceral and Subcutaneous Fat and Reverses Liver Steatosis in Diet-Induced Obese Mice
Tony Jourdan, Louiza Djaouti, Laurent Demizieux, Joseph Gresti, Bruno L Vergès, Pascal Degrace · 2010 · Diabetes
Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies
Anastasia S. Suraev, Nathaniel S. Marshall, Ryan G. Vandrey, Danielle McCartney, Melissa J. Benson, Iain S. McGregor, Ronald R. Grunstein, Camilla M. Hoyos · 2020 · Sleep Medicine Reviews
Impact of dietary fats on brain functions
Chianese, Rosanna, Coccurello, Roberto, Viggiano, Andrea, Scafuro, Marika, Fiore, Marco, Coppola, Giangennaro, Operto, Francesca Felicia, Fasano, Silvia, Laye, Sophie, Pierantoni, Riccardo et al. · 2018 · Current Neuropharmacology
The Novel Cannabinoid CB1 Receptor Neutral Antagonist AM4113 Suppresses Food Intake and Food-Reinforced Behavior but Does not Induce Signs of Nausea in Rats
Kelly S. Sink, Peter Joseph McLaughlin, Jodi Anne T. Wood, C. Brown, Pusheng Fan, Kiran V. Vemuri, Yan Pang, Teresa Olzewska, Ganesh A. Thakur, Alexandros Makriyannis et al. · 2007 · Neuropsychopharmacology
Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches
Dragana Nikolić, Niki Katsiki, Giuseppe Montalto, Esma R. Isenović, Dimitri P. Mikhailidis, Manfredi Rizzo · 2013 · Nutrients
The endocannabinoid system, eating behavior and energy homeostasis: The end or a new beginning?
Francisco Javier Bermúdez‐Silva, María‐Paz Viveros, John M. McPartland, Fernando Rodrı́guez de Fonseca · 2010 · Pharmacology Biochemistry and Behavior
Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities
Elliot D. Mock, Berend Gagestein, Mario van der Stelt · 2022 · Progress in Lipid Research
Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets
Isabel Matias, Stefania Petrosino, Alessandro Racioppi, Raffaele Capasso, Angelo Antonio Izzo, Vincenzo Di Marzo · 2008 · Molecular and Cellular Endocrinology
Safety of antiobesity drugs
Bernard M.Y. Cheung, Tommy Tsang Cheung, Nithushi Rajitha Samaranayake · 2013 · Therapeutic Advances in Drug Safety
SIRT1 Deacetylase in SF1 Neurons Protects against Metabolic Imbalance
Giorgio Ramadori, Teppei Fujikawa, Jason G. Anderson, Eric D. Berglund, Renata Frazão, Shaday Michán, Claudia Regina Vianna, David A. Sinclair, Carol Fuzeti Elias, Roberto Coppari · 2011 · Cell Metabolism
Peripheral, but Not Central, CB1 Antagonism Provides Food Intake–Independent Metabolic Benefits in Diet-Induced Obese Rats
Rubén Nogueiras, Christelle Veyrat‐Durebex, Paula M. Suchanek, Marcella Klein, Johannes Tschöp, Charles C. Caldwell, Stephen C. Woods, Gábor Wittmann, Masahiko Watanabe, Zsolt Liposits et al. · 2008 · Diabetes
Prevention of Plasticity of Endocannabinoid Signaling Inhibits Persistent Limbic Hyperexcitability Caused by Developmental Seizures
Kang Chen, Axel Dietmar Neu, Allyson L. Howard, Csaba Földy, Julio C. Echegoyen, Lutz G.W. Hilgenberg, Martin J. Smith, Ken Mackie, Iván Soltész · 2007 · Journal of Neuroscience
Comparison of a very low-calorie-ketogenic diet with a standard low-calorie diet in the treatment of obesity
Moreno, Basilio, Bellido, Diego, Sajoux, Ignacio, Goday, Albert, Saavedra, Dolores, Crujeiras, Ana B., Casanueva, Felipe F. · 2014 · Endocrine
Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
Van Gaal, Luc F., Scheen, André J., Rissanen, Aila M., Rössner, Stephan, Hanotin, Corinne, Ziegler, Olivier · 2008 · European Heart Journal
Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension
Jens Jordan, Volkan Yumuk, Markus Peter Schlaich, Peter M. Nilsson, Barbara Zahorska‐Markiewicz, Guido M. Grassi, Roland Erich Schmieder, Stefan Engeli, Nick Finer · 2012 · Journal of Hypertension
The Endocannabinoid System and Plant-Derived Cannabinoids in Diabetes and Diabetic Complications
Béla Horváth, Partha Mukhopadhyay, György Haskó, Pál Pacher · 2011 · American Journal Of Pathology
The therapeutic potential of second and third generation CB1R antagonists
Reşat Çınar, Malliga R. Iyer, George Kunos · 2020 · Pharmacology & Therapeutics
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, Esa R., den Hollander, Bjørnar, Farooq, Usman, Vashchinkina, Elena, Rajkumar, Ramamoorthy, Nutt, David J., Hyytiä, Petri, Dawe, Gavin S. · 2015 · Pharmacological Reviews
Rimonabant for overweight or obesity
Cíntia Chaves Curioni, Charles André · 2006 · Cochrane Database of Systematic Reviews
Effect of Orlistat on Weight Regain and Cardiovascular Risk Factors Following a Very-Low-Energy Diet in Abdominally Obese Patients
Bjørn Richelsen, Serena Tonstad, Stephan Rössner, Søren Toubro, LEO K. NISKANEN, Sten Madsbad, Pertti Mustajoki, Aila Rissanen · 2006 · Diabetes Care
The metabolic syndrome in hypertension: European society of hypertension position statement
Josep Redón, Renata Cífková, Stéphane Laurent, Peter M. Nilsson, Krzysztof Narkiewicz, Serap E. Erdine, Giuseppe Mancia · 2008 · Journal of Hypertension
From Surface to Nuclear Receptors: The Endocannabinoid Family Extends its Assets
Marco Pistis, Miriam Melis · 2010 · Current Medicinal Chemistry
Emerging Therapeutic Strategies for Obesity
Karen E. Foster‐Schubert, David E. Cummings · 2006 · Endocrine Reviews
Obesity, proteinuria and progression of renal failure
M. Praga, E. Morales · 2006 · Current opinion in nephrology and hypertension
Endocannabinoid System and Synaptic Plasticity: Implications for Emotional Responses
María‐Paz Viveros, Eva María Marco, Ricardo Llorente, Meritxell López‐Gallardo · 2007 · Neural Plasticity
Long-term Effects of Weight-Reducing Interventions in Hypertensive Patients Systematic Review and Meta-analysis
Karl Horvath · 2008 · Archives of Internal Medicine
Motion Sickness, Stress and the Endocannabinoid System
Choukèr, Alexander, Kaufmann, Ines, Kreth, Simone, Hauer, Daniela, Feuerecker, Matthias, Thieme, Detlef, Vogeser, Michael, Thiel, Manfred, Schelling, Gustav · 2010 · PLoS ONE
Metabolic Effects of Chronic Cannabis Smoking
Ranganath Muniyappa, Sara Sable, Ronald Ouwerkerk, Andrea Mari, Ahmed M. Gharib, Mary F. Walter, Amber B. Courville, Gail Hall, Kong Y. Chen, Nora D. Volkow et al. · 2013 · Diabetes Care
Obesity, Abdominal Obesity, and Insulin Resistance
Sydney A. Westphal · 2008 · Clinical cornerstone
CB1 antagonists for obesity—what lessons have we learned from rimonabant?
Vincenzo Di Marzo, Jean‐Pierre Després · 2009 · Nature Reviews Endocrinology
The emerging role of the endocannabinoid system in cardiovascular disease
Pál Pacher, Sabine Steffens · 2009 · Seminars in Immunopathology
Should peripheral CB1 cannabinoid receptors be selectively targeted for therapeutic gain?
George Kunos, Douglas Osei‐Hyiaman, Sándor Bátkai, Keith A. Sharkey, Alexandros Makriyannis · 2008 · Trends in Pharmacological Sciences
Is raising HDL a futile strategy for atheroprotection?
TISHA R. JOY, Robert Alexander Hegele · 2008 · Nature Reviews Drug Discovery
Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation
Tzu-Tang Wei, Mark Chandy, Masataka Nishiga, Angela Zhang, Kaavya Krishna Kumar, Dilip Thomas, Amit Manhas, Siyeon Rhee, Johanne Marie Justesen, Ian Y. Chen et al. · 2022 · Cell
The Endocannabinoid System and PPARs: Focus on Their Signalling Crosstalk, Action and Transcriptional Regulation
Fabio Arturo Iannotti, Rosa Maria Vitale · 2021 · Cells
Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy
Desirée Luis-Rodríguez · 2012 · World Journal of Diabetes
The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings
Ariane Mallat, Fatima Teixeira-Clerc, Vanessa Deveaux, Sylvie Manin, Sophie Lotersztajn · 2011 · British Journal of Pharmacology
Metabolic Syndrome Is Associated With Faster Degeneration of Bioprosthetic Valves
Martin Briand, Philippe Pîbarot, Jean‐Pierre Després, Pierre Voisine, Jean Gaston Dumesnil, François Dagenais, Patrick Mathieu · 2006 · Circulation
Obesity-hypertension: an ongoing pandemic
Emílio Antônio Francischetti, Virginia A. Genelhu · 2007 · International Journal of Clinical Practice
Cannabinoid CB1 receptor inverse agonists and neutral antagonists: Effects on food intake, food-reinforced behavior and food aversions
John D. Salamone, Peter Joseph McLaughlin, Kelly S. Sink, Alexandros Makriyannis, Linda A. Parker · 2007 · Physiology & Behavior
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angeliki M. Angelidi, Matthew J. Belanger, Alexander D. Kokkinos, Chrysi C. Koliaki, Christos Socrates Mantzoros · 2021 · Endocrine Reviews
Approximation of total visceral adipose tissue with a single magnetic resonance image
Ellen W. Demerath, Wei Shen, Miryoung Lee, Audrey C. Choh, Stefan A. Czerwinski, Roger M. Siervogel, Bradford Towne · 2007 · American Journal of Clinical Nutrition
Obesity: A Review of Pathogenesis and Management Strategies
Brinderjit Kaila, Maitreyi Raman · 2008 · Canadian Journal of Gastroenterology
Contribution of specific ceramides to obesity-associated metabolic diseases
Philipp Hammerschmidt, Jens C. Brüning · 2022 · Cellular and Molecular Life Sciences
The Endocannabinoid System and Energy Metabolism
Luigi Bellocchio, Cristina Cervino, Riccardo Pasquali, Uberto Pagotto · 2008 · Journal of Neuroendocrinology
Obesity treatment by very low-calorie-ketogenic diet at two years: reduction in visceral fat and on the burden of disease
Moreno, Basilio, Crujeiras, Ana B, Bellido, Diego, Sajoux, Ignacio, Casanueva, Felipe F · 2016 · Endocrine
Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome
Cesare Cremon, Vincenzo Stanghellini, Maria Raffaella Barbaro, Rosanna Francesca Cogliandro, Lara Bellacosa, Javier Santos, María Vicario, Marc Pigrau, Carmen Alonso, Beatriz Lobo et al. · 2017 · Alimentary Pharmacology & Therapeutics
Appetite Regulation: An Overview
Waljit Singh Dhillo · 2007 · Thyroid
CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health
Daniela Cota · 2007 · Diabetes/Metabolism Research and Reviews
Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor–Deficient Mice
Frédérique Dol-Gleizes, Réjane Paumelle, Virgile Visentin, Anne-Marie Marés, Perrine Desitter, Nathalie Hennuyer, Andries J. Gilde, Bart Staels, Paul Schaeffer, Françoise Bono · 2008 · Arteriosclerosis Thrombosis and Vascular Biology
Lifestyle and Pharmacological Approaches to Weight Loss: Efficacy and Safety
George A. Bray · 2008 · The Journal of Clinical Endocrinology & Metabolism
New Drugs for Type 2 Diabetes Mellitus
Andrew J. Krentz, Mayank Patel, Clifford J. Bailey · 2008 · Drugs
Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice
Michel Alexander Steiner, Klaus Wanisch, Krisztina Monory, Giovanni Marsicano, Edilio Borroni, Heidrun Bächli, F Holsboer, Beat Lutz, Carsten Tobias Wotjak · 2007 · The Pharmacogenomics Journal
Endocannabinoid signaling and food addiction
Claudio D’Addario, Maria Vittoria Micioni Di Bonaventura, Mariangela Pucci, A. Romano, Silvana Gaetani, Roberto Ciccocioppo, Carlo Cifani, Mauro Maccarrone · 2014 · Neuroscience & Biobehavioral Reviews
Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats
Philip Janiak, Bruno Poirier, Jean‐Pierre Bidouard, C. Cadrouvele, Françoise Pierre, Laurent Gouraud, Isabelle Barbosa, Jürgen Dedio, Jean‐Pierre Maffrand, Gérard Le Fur et al. · 2007 · Kidney International
Behavior therapy for obesity: where are we now?
Sarwer, David B, von Sydow Green, Amy, Vetter, Marion L, Wadden, Thomas A · 2009 · Current Opinion in Endocrinology, Diabetes & Obesity
Central control of thermogenesis
John C. Clapham · 2011 · Neuropharmacology
Modulation of the Endocannabinoid System in Cardiovascular Disease
Pál Pacher, Partha Mukhopadhyay, Mohanraj Rajesh, Grzegorz Godlewski, Sándor Bátkai, George Kunos · 2008 · Hypertension
Long-term effects of weight-reducing diets in hypertensive patients
Andrea Siebenhofer, Klaus Jeitler, Andrea Berghold, Andreas Waltering, Lars G. Hemkens, Thomas Semlitsch, Christoph Pachler, Reinhard Strametz, Karl Horvath · 2011 · Cochrane Database of Systematic Reviews
The Metabolic Syndrome in Women
J Gabriel Schneider, CHRISTINE M. TOMPKINS, Roger Scott Blumenthal, Samia Mora · 2006 · Cardiology in Review
Rimonabant: A Cannabinoid Receptor Type 1 Blocker for Management of Multiple Cardiometabolic Risk Factors
Eli V. Gelfand, Christopher Paul Cannon · 2006 · Journal of the American College of Cardiology
Rise and fall of anti-obesity drugs
Mingfang Li · 2011 · World Journal of Diabetes
Associations Between Cannabis Use and Physical Health Problems in Early Midlife
Madeline H. Meier, Avshalom Caspi, Magdalena Cerdá, Robert John Hancox, HonaLee Harrington, Renate Houts, Richie Poulton, Sandhya Ramrakha, W. Murray Thomson, Terrie E. Moffitt · 2016 · JAMA Psychiatry
Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance
Scott M. Grundy · 2006 · Clinical cornerstone
Drug Treatment of the Overweight Patient
Bray, George A., Ryan, Donna H. · 2007 · Gastroenterology
Obesity‐related Changes in High‐density Lipoprotein Metabolism
Arshag D. Mooradian, Michael John Haas, Kent R. Wehmeier, Norman C.W. Wong · 2008 · Obesity
Long-term effects of weight-reducing drugs in people with hypertension
Andrea Siebenhofer, Klaus Jeitler, Karl Horvath, Andrea Berghold, Nicole A. S. Posch, Jutta Meschik, Thomas Semlitsch · 2016 · Cochrane Database of Systematic Reviews
Interrelationships Between Inflammation, C‐Reactive Protein, and Insulin Resistance
Chiadi E. Ndumele, Aruna D. Pradhan, Paul M. Ridker · 2006 · Journal of the CardioMetabolic Syndrome
Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo‐controlled study
Tuba Esfandyari, Michael Camilleri, Irene J. Ferber, Duane D. Burton, Kari L. Baxter, Alan R. Zinsmeister · 2006 · Neurogastroenterology & Motility
Treatment of overweight and obesity: Lifestyle, pharmacologic, and surgical options
Christopher Paul Cannon, Amit Kumar · 2009 · Clinical cornerstone
Cannabinoids and Endocannabinoids in Metabolic Disorders with Focus on Diabetes
Vincenzo Di Marzo, Fabiana Piscitelli, Raphael Mechoulam · 2011 · Handbook of experimental pharmacology
Metabolic syndrome: the danger signal in atherosclerosis
Patrick Mathieu, Philippe Pîbarot, Jean‐Pierre Després · 2006 · Vascular Health and Risk Management
Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs
Pradeep J. Nathan, Barry Vincent O’Neill, Antonella Napolitano, Edward Thomas Bullmore · 2010 · CNS Neuroscience & Therapeutics
Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents
Guy Griebel, Philippe Pichat, Sandra Beeské, Thibaud Leroy, Nicolas Redon, Agnès Jacquet, Dominique Françon, Lionel Bert, Luc Even, Mati Lopez‐Grancha et al. · 2015 · Scientific Reports
Fatty liver and the metabolic syndrome
Brent A. Neuschwander‐Tetri · 2007 · Current Opinion in Gastroenterology
Metabolic syndrome and renal disease
Anna Gluba-Brzózka, Dimitri P. Mikhailidis, Gregory Y.H. Lip, Simon Hannam, Jacek Rysz, Maciej Banach · 2012 · International Journal of Cardiology